What could cause a persistent banana-like taste (dysgeusia) and what initial evaluation should be performed?

Persistent Banana-Like Taste (Dysgeusia)

A persistent banana-like taste represents dysgeusia (qualitative taste distortion) and warrants systematic evaluation for medication effects, oral candidiasis, psychiatric distress, and less commonly, viral infections including COVID-19, with initial assessment focusing on medication review, oral examination, and targeted testing based on clinical findings.

Understanding the Symptom

Dysgeusia is a distortion or perversion in taste perception that occurs in the presence of a tastant, distinct from phantogeusia (taste perception without a stimulus). This specific banana-like taste represents a qualitative gustatory impairment rather than diminished taste sensitivity 1, 2.

Key distinction: Unlike hypogeusia (decreased taste sensitivity with elevated thresholds), dysgeusia typically occurs with normal taste thresholds and often does not resolve spontaneously 1.

Primary Etiologies to Consider

1. Medication-Induced (Most Common Reversible Cause)

Medications are among the most frequent causes of dysgeusia 3. Priority offending drug classes include:

• Keratolytic agents (highest reported association)
• Chemotherapeutic agents
• Antihistamines
• Antibiotics
• ACE inhibitors
• Antifungals, antivirals, antimalarials

Critical action: Complete medication reconciliation is mandatory, including over-the-counter medications and supplements. Drug-induced dysgeusia typically resolves completely within 2 months of cessation 1, 3.

2. Oral Candidiasis

Oral candidiasis was identified in 3 of 14 dysgeusia patients in systematic evaluation 1.

Examination requirements:

• Visual inspection for white plaques, erythema, angular cheilitis
• Consider Candida culture if clinical suspicion exists
• Particularly relevant in patients with diabetes, immunosuppression, or recent antibiotic use

3. Psychiatric Distress

Psychiatric etiology was the most common cause in dysgeusia patients (8 of 14 cases) 1.

Assessment should include:

• Depression screening
• Anxiety disorders
• Stress evaluation
• History of somatization

Important caveat: Dysgeusia from psychiatric causes typically does not improve with standard interventions and may require psychiatric management 1.

4. COVID-19 and Viral Infections

While the provided guidelines focus on anosmia, dysgeusia frequently accompanies COVID-19 infection 4. Multiple studies documented dysgeusia occurring with or without anosmia in COVID-19 patients 4.

Consider COVID-19 testing if:

• Recent onset (within days to weeks)
• Accompanying anosmia or hyposmia
• Other systemic symptoms (fever, fatigue, myalgia)
• Known exposure

5. Hyposalivation (Xerostomia)

Reduced salivary flow was associated with dysgeusia in 1 of 14 patients 1.

Evaluate for:

• Medication effects (anticholinergics, antihistamines)
• Sjögren syndrome
• Radiation therapy history
• Dehydration

6. Neurological Causes

Damage to gustatory pathways (facial nerve VII, glossopharyngeal nerve IX, vagus nerve X) can cause dysgeusia 2, 5.

Red flags requiring neurological evaluation:

• Unilateral symptoms
• Associated cranial nerve deficits (facial weakness, hearing loss, dysphagia)
• History of head trauma, stroke, or skull base pathology
• Progressive symptoms

Initial Evaluation Algorithm

Step 1: Medication Review

• Document all current medications with start dates
• Correlate symptom onset with medication initiation
• Consider trial discontinuation of suspect agents (if medically appropriate)

Step 2: Oral Examination

• Inspect for candidiasis (white plaques, erythema)
• Assess salivary flow (observe pooling, ask about dry mouth)
• Examine for mucosal lesions, dental pathology

Step 3: Targeted History

• Timing: Acute (days-weeks) vs. chronic (months)
• Associated symptoms: Anosmia, nasal congestion, fever, neurological symptoms
• Psychiatric history: Depression, anxiety, recent stressors
• Medical conditions: Diabetes, kidney disease, liver disease, immunosuppression
• Recent infections: Upper respiratory infections, COVID-19 exposure

Step 4: Selective Testing

• COVID-19 testing if acute onset with respiratory symptoms or exposure
• Candida culture if oral examination suggests infection
• Salivary flow measurement if xerostomia suspected
• Serum zinc level only if nutritional deficiency suspected (though zinc deficiency was NOT found in dysgeusia patients in systematic evaluation 1)

Note: Serum copper and zinc levels were not decreased in any dysgeusia patients in one systematic study, questioning routine zinc supplementation 1.

Management Approach

For Drug-Induced Dysgeusia:

• Discontinue or substitute offending medication (if possible)
• Expected resolution: 2 months after cessation 1
• Monitor for improvement

For Oral Candidiasis:

• Antifungal therapy (topical or systemic based on severity)
• Address predisposing factors

For Psychiatric Etiology:

• Gabapentin may provide benefit (10 of 20 patients responded in controlled trial for oral dysesthesia) 6
• Psychiatric referral for underlying mood disorder management
• Realistic expectation: Symptoms often persist despite treatment 1

For Hyposalivation:

• Dietary modifications, hydration
• Saliva substitutes, systemic sialagogues (cevimeline, pilocarpine) 6
• Address underlying cause

For Idiopathic Cases:

• Trial of zinc supplementation may be considered in idiopathic dysgeusia 5, though evidence is limited
• Supportive care
• Reassurance regarding benign nature

Critical Pitfalls to Avoid

1. Do not routinely check zinc/copper levels - these were normal in all dysgeusia patients in systematic evaluation 1

2. Do not expect resolution in psychiatric cases - dysgeusia from psychiatric distress typically persists despite interventions 1

3. Do not overlook medication timing - carefully correlate symptom onset with medication changes

4. Do not dismiss as purely psychological - systematic evaluation identifies treatable causes in majority of cases

5. Do not order extensive neuroimaging without focal neurological findings - reserve for patients with cranial nerve deficits or progressive symptoms 7, 5

When to Refer

• Neurology: Focal neurological deficits, progressive symptoms, suspected cranial neuropathy
• Psychiatry: Primary psychiatric etiology identified, refractory symptoms with mood disorder
• ENT: Persistent symptoms after initial evaluation, need for specialized gustatory testing
• Rheumatology: Suspected Sjögren syndrome or other autoimmune condition

Prognosis

Drug-induced dysgeusia: Excellent prognosis with complete resolution expected within 2 months of drug cessation 1

Psychiatric etiology: Poor prognosis for symptom resolution; focus on managing underlying psychiatric condition 1

Oral candidiasis: Good prognosis with appropriate antifungal therapy

Idiopathic: Variable; some cases resolve spontaneously, others persist 1